Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial

Regulatory Peptides

Volumn 182, Issue 1, 2013, Pages 1-6

  Esteghamati, Alireza ^a   Noshad, Sina ^a   Rabizadeh, Soghra ^a   Ghavami, Mojgan ^a   Zandieh, Ali ^a   Nakhjavani, Manouchehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Leptin; Metformin; Omentin; Pioglitazone; RCT

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMENTIN; PIOGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EFFECT SIZE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; LECTINS; LEPTIN; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84873957568     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.12.005     Document Type: Article

References (42)

1. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
2. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001, 60:329-339.
3. Rasouli N., Kern P.A. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93:S64-S73.
4. Wisse B.E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004, 15:2792-2800.
5. Whitmer R.A. The epidemiology of adiposity and dementia. Curr Alzheimer Res 2007, 4:117-122.
6. Kieffer T.J., Habener J.F. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 2000, E1-E14.
7. Yang R., Lee M., Hu H. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, E1253-E1261.
8. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., Shuldiner A.R., Fried S.K., McLenithan J.C., Gong D.W. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
9. DeSouzaBatista C.M., Yang R.Z., Lee M.J. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 1655-1661.
10. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33.
11. Tan B.K., Adya R., Farhatullah S., Lewandowski K.C., O'Hare P., Lehnert H., Randeva H.S. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
12. Shibata R., Ouchi N., Kikuchi R., Takahashi R., Takeshita K., Kataoka Y., Ohashi K., Ikeda N., Kihara S., Murohara T. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219:811-814.
13. Liu R., Wang X., Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011, 93:21-25.
14. Nakhjavani M., Esteghamati A., Tarafdari A.M., Nikzamir A., Ashraf H., Abbasi M. Association of plasma leptin levels and insulin resistance in diabetic women: a cross-sectional analysis in an Iranian population with different results in men and women. Gynecol Endocrinol 2011, 27:14-19.
15. Esteghamati A., Noshad S., Khalilzadeh O., Morteza A., Nazeri A., Meysamie A., Nakhjavani M. Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. Arch Med Res 2011, 42:244-251.
16. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004, 53(Suppl. 1):S152-S158.
17. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006, 189:47-60.
18. Martin S.S., Qasim A., Reilly M.P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008, 52:1201-1210.
19. Cobitz A.R., Ambery P. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Response to Nathan et al. Diabetes Care 2009, 32:e58. [author rely e9].
20. Gerstein H.C. Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. Nat Rev Endocrinol 2009, 5:270-275.
21. Bennett W.L., Maruthur N.M., Singh S., Segal J.B., Wilson L.M., Chatterjee R., Marinopoulos S.S., Puhan M.A., Ranasinghe P., Block L., Nicholson W.K., Hutfless S., Bass E.B., Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.
22. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34(Suppl. 1):S62-S69.
23. Akbarzadeh S., Nabipour I., Assadi M., Movahed A., Jafari S., Motamed N., Nazem H., Haraghy M., Pourbehi A., Bargahi A., Hajian N. The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels. Cytokine 2012, 295-299.
24. Tan B.K., Pua S., Syed F., Lewandowski K.C., O'Hare J.P., Randeva H.S. Decreased plasma omentin-1 levels in type 1 diabetes mellitus. Diabet Med 2008, 25:1254-1255.
25. Kennedy A., Gettys T.W., Watson P., Wallace P., Ganaway E., Pan Q., Garvey W.T. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997, 82:1293-1300.
26. Moreno-Navarrete J.M., Catalan V., Ortega F., Gomez-Ambrosi J., Ricart W., Fruhbeck G., Fernandez-Real J.M. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010, 7:27.
27. Tan B., Adya R., Farhatullah S., Chen J., Lehnert H., Randeva H. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010, 3023-3031.
28. Shaker M., Mashhadani Z., Mehdi A. Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients. Oman Med J 2010, 289-293.
29. Yan P., Li L., Yang M., Liu D., Liu H., Boden G., Yang G. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011, 368-374.
30. Karlsson H.K., Hallsten K., Bjornholm M., Tsuchida H., Chibalin A.V., Virtanen K.A., Heinonen O.J., Lonnqvist F., Nuutila P., Zierath J.R. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 2005, 54:1459-1467.
31. Yilmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., Celikel C., Imeryuz N., Kalayci C., Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011, 91-97.
32. Utzschneider K.M., Kahn S.E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006, 91:4753-4761.
33. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
34. Kashi M.R., Torres D.M., Harrison S.A. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28:396-406.
35. Paz-Filho G., Wong M.L., Licinio J. Ten years of leptin replacement therapy. Obes Rev 2011, 12:e315-e323.
36. Considine R., Sinha M., Heiman M., Kriauciunas A., Stephens T., Nyce M., Ohannesian J., Marco C., McKee L., Bauer T. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 292-295.
37. Leyva F., Godsland I.F., Ghatei M., Proudler A.J., Aldis S., Walton C., Bloom S., Stevenson J.C. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998, 18:928-933.
38. Doogue M.P., Begg E.J., Moore M.P., Lunt H., Pemberton C.J., Zhang M. Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol 2009, 68:875-882.
39. Miyazaki Y., DeFronzo R.A. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008, 10:1204-1211.
40. Oz O., Tuncel E., Eryilmaz S., Fazlioglu M., Gul C.B., Ersoy C., Ocak N., Dirican M., Cangur S., Baran I., Imamoglu S. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine 2008, 33:101-105.
41. Matsui Y., Hirasawa Y., Sugiura T., Toyoshi T., Kyuki K., Ito M. Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. Biol Pharm Bull 2010, 33:963-970.
42. Sharma P.K., Bhansali A., Sialy R., Malhotra S., Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006, 65:722-728.